Compare
NAVs as of 20 Aug 2026
Add a second fund to compare. Until then every figure below is shown against the Large & Mid Cap Fund median (36 funds), which is the only comparison one fund can support.
Growth of ₹100 (rebased over the selected window)
Common period 13 Sep 2024 – 20 Aug 2026, limited by ITI Large & Mid Cap Fund. Every series is rebased to ₹100 at the start of this window. Benchmark lines are the category index WealthTicker measures against, which is not always the benchmark the scheme itself declares — the fund page’s Scheme Info names that one.
View as table
| Date | ITI Large & Mid Cap Fund | Nifty Midcap 150 |
|---|---|---|
| 13 Sep 2024 | ₹100.00 | ₹100.00 |
| 11 Nov 2024 | ₹96.82 | ₹93.51 |
| 09 Jan 2025 | ₹94.15 | ₹93.17 |
| 09 Mar 2025 | ₹85.63 | ₹82.43 |
| 06 May 2025 | ₹89.85 | ₹88.53 |
| 04 Jul 2025 | ₹100.14 | ₹99.02 |
| 01 Sep 2025 | ₹95.10 | ₹95.14 |
| 30 Oct 2025 | ₹100.48 | ₹99.84 |
| 28 Dec 2025 | ₹97.08 | ₹100.00 |
| 25 Feb 2026 | ₹94.84 | ₹98.96 |
| 24 Apr 2026 | ₹94.35 | ₹98.58 |
| 22 Jun 2026 | ₹99.85 | ₹103.98 |
| 20 Aug 2026 | ₹102.72 | ₹105.40 |
| Metric | ITI · Direct NAV ₹10.35 Very High risk ★★☆☆☆ 1Y | Category median Large & Mid Cap Fund · 36 funds |
|---|---|---|
| +5.95% | +6.71% | |
| — | +16.28% | |
| — | +15.15% | |
| — | +15.07% | |
| +1.40% | +15.33% | |
| +7.64% | — | |
| — | +17.48% | |
| — | +16.77% | |
| — | +16.31% | |
| Risk | ||
| 17.37% | 14.81% | |
| -0.03 | 0.61 | |
| -0.04 | 0.82 | |
| -20.18% | -35.67% | |
| Nifty Midcap 150 | — | |
| — | +0.30% | |
| — | 0.83 | |
| — | 84.1% | |
| — | 78.7% | |
| 1.06% | 1.07% | |
| ₹740.26Cr | ₹3,576Cr | |
| 0.50% | — | |
| None | — | |
| ₹500 | — | |
| ₹5.00K | — | |
| 132% | 42% | |
| Alok Ranjan · 1.8y | — | |
| 13 Sep 2024 | — | |
| 101 | — | |
| 19.3% | — | |
| -0.0% | — | |
Best marks the strongest value in a row, and only where the gap is bigger than noise — a near-tie is left unmarked rather than dressed up as a result. SIP XIRR is a ₹10,000/month instalment over 5 years of real NAV history. Nothing here is supplied by a fund house. For research only — not investment advice.